By antigenic and genetic characterization of canine parvovirus type 2 (CPV-2) strains collected in 2001 and 2002 in Italy, it was possible to observe the spread of viruses with an unusual mutation, Glu-426, affecting a major antigenic epitope of CPV-2. Out of 67 strains analyzed, 49 (73.13%) were characterized as CPV-2a, 6 (8.95%) were characterized as CPV-2b, and 12 (17.91%) were characterized...

20.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419 20.1.1 State-Space Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419 20.1.2 Latent Dirichlet Allocation . . . . . . . . . . . ...

A prediction of the galaxy cluster cooling flow model is that as gas cools from the ambient cluster temperature, emission lines are produced in gas at subsequently decreasing temperatures. Gas passing through 10 K emits in the lines of O VI λλ1032, 1035, and here we report a FUSE study of these lines in three cooling flow clusters, Abell 426, Abell 1795, and AWM 7. No emission was detected from...

To escape immune recognition, viruses acquire amino acid substitutions in class I human leukocyte antigen (HLA)-presented cytotoxic T-lymphocyte (CTL) epitopes. Such viral escape mutations may (i) prevent peptide processing, (ii) diminish class I HLA binding, or (iii) alter T-cell recognition. Because residues 418 to 426 of the hypervariable influenza A virus nucleoprotein (NP(418-426)) epitope...

Background: Loss of hearing is a non-visible disability (NVD) and the second most common congenital pathology. Apart from hearing loss, further disability in these domains has been reported like development of language, speech, cognition, and other evolving domains. These can be prevented by early identification and intervention. The aim of this study was to assess the outcomes of neonatal hear...

[This corrects the article on p. 426 in vol. 8, PMID: 28955291.].

2535 Background: MBP-426 is a novel liposome encapsulated oxaliplatin (L-OHP) formulation bound to human transferrin, developed to improve the safety and efficacy of L -OHP through the prolongation of circulation time and by targeting transferrin receptors on tumor cells. In vitro, MBP-426 is effective against various human cancer cell lines. This study assessed the toxicity and safety of intra...